Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
99.90    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.30 (1.312%)
Market Cap: £607.58m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Directorate Change

31 Dec 2021 07:00

RNS Number : 6395W
Syncona Limited
31 December 2021
 

Syncona Limited

 

Directorate Change

 

31 December 2021

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, notes that as previously announced, Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.

 

Virginia Holmes will become Senior Independent Director and Gian Piero Reverberi will become Chair of the Remuneration Committee, in each case from 1 January 2022.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

Company Secretary

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758228

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

 

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFELFSDEFSEEE
Date   Source Headline
18th May 20217:00 amRNSNotice of Results
18th May 20217:00 amRNSFreeline reports Q1 results
12th May 20213:05 pmRNSAutolus to present additional data in AUTO1
12th May 20211:18 pmRNSDirector/PDMR Shareholding
11th May 202112:05 pmRNSAchilles reports Q1 financial results
7th May 20217:00 amRNSGyroscope Therapeutics update on proposed IPO
6th May 202112:05 pmRNSAutolus reports Q1 2021 Financial Results
4th May 20217:00 amRNSUpdate on Gyroscope proposed IPO in the US
19th Apr 202112:05 pmRNSAutolus appoints non-executive Chair
19th Apr 20217:00 amRNSGyroscope files registration statement
6th Apr 20214:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSFreeline Reports Financial Results
31st Mar 20217:00 amRNSAchilles update on IPO
30th Mar 202112:04 pmRNSDirector/PDMR Shareholding
26th Mar 20217:06 amRNSGyroscope announces additional financing plans
26th Mar 20217:00 amRNSSyncona cornerstones $148m Series C in Gyroscope
25th Mar 202111:13 amRNSUpdate on Achilles’ proposed IPO
4th Mar 202112:10 pmRNSAutolus Reports Full Year 2020 Financial Results
2nd Mar 20217:00 amRNSAchilles files registration statement
12th Feb 20213:49 pmRNSGyroscope Announces Positive Interim Data
11th Feb 20217:00 amRNSNew commitment to Quell in largest ever Series A
11th Feb 20217:00 amRNSQuarterly and Business Update
10th Feb 20217:00 amRNSAutolus announces pricing of public offering
8th Feb 202112:09 pmRNSFreeline Updates Clinical Development Plan
5th Feb 20217:00 amRNSAchilles announces additional financing plans
5th Feb 20217:00 amRNSAchilles data and safety committee review
6th Jan 20217:00 amRNSAutolus Business Outlook
21st Dec 20207:00 amRNSVirginia Holmes Appointed Non-Executive Director
14th Dec 202012:05 pmRNSFreeline reports updated clinical data
7th Dec 20205:05 pmRNSAutolus presents additional data on AUTO3
7th Dec 20207:05 amRNSAutolus presents additional data on AUTO1
27th Nov 20204:35 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNSSyncona founds Purespring with a £45m Series A
19th Nov 20207:00 amRNSHalf-year Report
5th Nov 202012:11 pmRNSAutolus reports Q3 2020 Financial Results
3rd Nov 20208:30 amRNSNotice of Results
2nd Nov 20207:00 amRNSDirectorate Change
30th Oct 20207:00 amRNSFreeline H1 Results and Business Highlights
18th Sep 20208:10 amRNSAutolus presents additional data on AUTO3
14th Sep 20201:05 pmRNSSyncona expands cell therapy portfolio
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
10th Aug 20207:00 amRNSQuarterly Update
7th Aug 20207:00 amRNSFreeline update on IPO
6th Aug 202012:10 pmRNSAutolus reports Q2 2020 Financial Results
3rd Aug 202011:30 amRNSUpdate on Freeline proposed IPO in the U.S.
28th Jul 202012:00 pmRNSResult of AGM
20th Jul 20207:00 amRNSFreeline files registration statement
13th Jul 20204:51 pmRNSFreeline publishes further data for FLT180a
9th Jul 20201:00 pmRNSIssue of shares pursuant to Incentive Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.